Sentences with phrase «cancer cell resistance»

«Unstable chromosomes have been associated with cancer cell resistance to a number of drugs,» says Rebecca Burrell of Cancer Research UK's London Research Institute.

Tissue engineering provides a more practical means for researchers to study cell behavior, such as cancer cell resistance to therapy, and test new drugs or combinations of drugs to treat many diseases.

Not exact matches

Working in cell cultures and mice, researchers at Johns Hopkins have found that an experimental drug called fostamatinib combined with the chemotherapy drug paclitaxel may overcome ovarian cancer cells» resistance to paclitaxel.

As a result, P - gp causes resistance of the diseased cells to a majority of drugs currently available for the treatment of cancer, as well as drugs used for treatment of infectious diseases like HIV / AIDS.

But Whitehead Institute researchers have found a mechanism underlying this resistance — a mechanism that naturally occurs in many diverse cancer types and that may expose vulnerabilities to drugs that spur the natural cell - death process.

Now a University of Colorado Cancer Center study published online ahead of print in the journal Oncogene offers compelling evidence explaining this failure and offering a possible strategy for the use of retinoic acid or other retinoids against some breast cancers: Because early clinical trials are often offered to patients who have already tried other more established therapies, breast cancer cells may have been pushed past an important tipping point that offers retinoic acid resisCancer Center study published online ahead of print in the journal Oncogene offers compelling evidence explaining this failure and offering a possible strategy for the use of retinoic acid or other retinoids against some breast cancers: Because early clinical trials are often offered to patients who have already tried other more established therapies, breast cancer cells may have been pushed past an important tipping point that offers retinoic acid resiscancer cells may have been pushed past an important tipping point that offers retinoic acid resistance.

The ability for cancer cells to develop resistance to chemotherapy drugs — known as multi-drug resistance — remains a leading cause for tumor recurrence and cancer metastasis, but recent findings offer hope that oncologists could one day direct cancer cells to «turn off» their resistance capabilities.

The use of proteasome inhibitors to treat cancer has been greatly limited by the ability of cancer cells to develop resistance to these drugs.

«For years, researchers have focused on delivering more chemotherapy drugs into cancer cells using nanoparticles, without targeting the root of drug resistance,» He said.

Women with high levels of FGF1 were less likely to respond to platinum - based drugs, but blocking the gene makes their cells lose their resistance (British Journal of Cancer, DOI: 10.1038 / bjc.2012.410).

While researchers have long worked with nanoparticles for drug delivery, the findings put forth by He and his team represent a crucial breakthrough in addressing multidrug resistance in cancer cells.

A new study by researchers at The Ohio State University Comprehensive Cancer Center — Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC — James) has identified a mechanism by which cancer cells develop resistance to a class of drugs called fibroblast growth factor receptor (FGFR) inhibCancer Center — Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC — James) has identified a mechanism by which cancer cells develop resistance to a class of drugs called fibroblast growth factor receptor (FGFR) inhibCancer Hospital and Richard J. Solove Research Institute (OSUCCC — James) has identified a mechanism by which cancer cells develop resistance to a class of drugs called fibroblast growth factor receptor (FGFR) inhibcancer cells develop resistance to a class of drugs called fibroblast growth factor receptor (FGFR) inhibitors.

Researchers at Roswell Park Cancer Institute (RPCI) have identified a mechanism of breast cancer cells that leads to chemotherapy resistance in inflammatory breast cCancer Institute (RPCI) have identified a mechanism of breast cancer cells that leads to chemotherapy resistance in inflammatory breast ccancer cells that leads to chemotherapy resistance in inflammatory breast cancercancer.

«Breakthrough technique combats cancer drug resistance: Researchers «turn off» multi-drug resistance capabilities in cancer cells.»

Although proteasome inhibitors are very efficient in selective killing of cancer tumor cells grown in a dish (in - vitro), their success in the clinic has largely been undermined by the development of resistance — mechanisms of which are poorly understood.

Cancer stem - like cells are thought to be the root cause of chemotherapy resistance, leading to treatment failure in patients with advanced disease and the triggers of tumour recurrence and metastasis (regrowth).

Analyzing data from thousands of cancer lines and tumors, the researchers found that those demonstrating resistance to proteasome inhibitor drugs were marked by suppressed expression of one or more of the cells» proteasome cap subunits (which are a subsets of the larger proteasome).

Designing molecules that selectively target thiols produced by cancer cells that cause drug resistance is the focus of many years» work by Dimmock, Das and their collaborators.

Das explained that since the compounds they've developed make cancer cells more sensitive to attack, they also remove resistance to standard chemotherapy drugs — a serious problem in current therapies.

«Study identifies how cancer cells may develop resistance to FGFR inhibitors.»

Adult drug resistant cancer cells may contribute to this problem, and the authors discuss these and other cancer drug resistance mechanisms in their recent publication in the September issue of the journal Cancers.

He and his group had been looking for evidence that normal cells in the cancer's environment contribute to chemotherapy resistance.

The team found that if they raised glutathione levels in cancer cells in the lab, they reversed resistance to the drug erlotinib, and the treatment was once again able to kill cancer cells.

Although alternative drugs are available once erlotinib stops working, these are much more expensive — and they can also stop working due to cancer cells developing resistance.

«Recent studies suggest that epigenetic modifications may contribute to the development of cancer progenitor cells that can induce drug resistance and the relapse of different types of cancer,» said Sibaji Sarkar, PhD, instructor of medicine at BUSM.

Such a lag time, says Hahn, could allow cancer cells to develop resistance to a drug by finding some other way to maintain their telomeres.

The drug that they have developed appears to target cancer stem cell activity, which suggests it will prevent metastatic recurrence and be useful in combatting drug resistance.»

Unfortunately, the drug usually stops working within a few months, due to cancer cells developing resistance to the treatment.

«We've also started exchanging ideas and information with scientists facing related challenges, such as resistance to herbicides in weeds and resistance to drugs in cancer cells,» Tabashnik said.

My cancer systems biology team at the University of California, Merced, is tackling diagnosis and treatment of therapy - resistant cancers by elucidating the network of changes within cells as a way to identify new drug targets and circumvent cancer resistance.

While the combination of targeted therapies improves patient outcomes, any remaining cancer cells can lead to drug resistance.

«Further research into the detailed mechanisms underlying ASIS in naked mole - rats may shed new light on cancer resistance in the mole - rats and contribute to the generation of non-tumorigenic human - iPSCs, enabling safer cell - based therapeutics,» said Kyoko Miura, an assistant professor at Hokkaido University.

Researchers targeting colorectal cancer stem cells — the root cause of disease, resistance to treatment and relapse — have discovered a mechanism to mimic a virus and potentially trigger an immune response to fight the cancer like an infection.

«Immune cells help reverse chemotherapy resistance in ovarian cancer.»

Tests with kidney cancer and two human uterine sarcoma cell lines, one with multidrug resistance, showed that 10 of these new compounds were impressively potent against all three cell lines, the researchers reported.

Semenza says previous studies have shown that resistance to chemotherapy arises from the hardy nature of cancer stem cells, which are often found in the centers of tumors, where oxygen levels are quite low.

The regrowth of cancer stem cells is responsible for the drug resistance that develops in many breast tumors and the reason that for many patients, the benefits of chemo are short - lived.

Interferon - inducible protein 6 - 16 (IFI 6 - 16), a protein not previously known to be associated with other misfolding diseases but that was uniquely found misfolded in the urine of women with preeclampsia, is known to help prevent cell death and, in breast cancer cells, is responsible for resistance to treatment.

In animal and cell culture studies, the drug inhibited growth both in estrogen - dependent breast cancer cells and in cells that had developed resistance to the anti-estrogen tamoxifen and / or to the aromatase inhibitors, two of the most widely used types of drugs to prevent and treat estrogen - dependent breast cancer.

This analysis, done on separate samples from the same patient, revealed that many of the affected genes confer advantages to cancer cells by, for example, enhancing cell migration or resistance to chemotherapy.

Many investigators had assumed that once breast cancer cells developed resistance to tamoxifen, they would be resistant to all drugs that target the estrogen receptor, McDonnell explained.

Cancer stem cells are strongly associated with the growth and recurrence of all cancers and are especially difficult to eradicate with normal treatment, which also leads to tumours developing resistance to other types of therapy.

The new study shows that a «constitutively active» signaling circuit can trigger cells to grow into tumors and drive therapy resistance in advanced prostate cancer.

A new study led by scientists from the Florida campus of The Scripps Research Institute (TSRI) sheds light on a signaling circuit in cells that drives therapy resistance in prostate cancer.

Currently, if breast cancer cells develop resistance to these therapies, patients are usually treated with toxic chemotherapy agents that have significant side effects.

Cancer stem cells can be considered the most dangerous type of cancer cells, as they appear to have an inherent resistance to the chemotherapeutic drugs used Cancer stem cells can be considered the most dangerous type of cancer cells, as they appear to have an inherent resistance to the chemotherapeutic drugs used cancer cells, as they appear to have an inherent resistance to the chemotherapeutic drugs used today.

The authors said their results, which they have made publicly available, constitute an invaluable resource to help clinicians predict which chemotherapies will be most effective against tumor cells with particular genetic mutations, and how to rationally combine therapies to prevent cancers from developing resistance.

In addition, cancer cells» susceptibility to these agents varies widely, and tumors often develop resistance to drugs that initially seem effective.

Cancer stem cells, a type of self - renewing cell found in tumors, are of particular interest because they are the main cell type responsible for tumor progression and for resistance to chemotherapy and radiotherapy, and therefore a major cause of tumor recurrence after treatment.

The common theory is that the cancer cell develops «internal resistance to treatment,» and overrides the toxic effects of the drug.